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OBJECTIVE: This study sought to evaluate the prevalence of human papillomavirus (HPV) types 16 and 18 in
women with clinical stage IB cervical cancer treated by radical hysterectomy with pelvic lymphadenectomy as
well as to establish a correlation between HPV type and cancer prognosis.
METHODS: A single-center cohort study was conducted with 86 patients who had undergone radical
hysterectomy for stage I cervical cancer. Prognostic factors and the presence of HPV 16 and 18 were analyzed
using a polymerase chain reaction assay. A univariate analysis using Kaplan-Meier curves was conducted to
estimate survival.
RESULTS: The prevalence of HPV 16 in the study group was 65.3%, and the prevalence of HPV 18 was 33.3%.
The prevalence of infection with both viruses was 26.9%. Overall survival at 5 years was 91% among women
with HPV 18 and 96% among those without this virus type (p=0.133). Among the women with HPV 16, the
overall survival was 94%, whereas this rate was 96% among those without this virus type (p=0.663). Disease-
free survival was unaffected by the presence of HPV type 16 or 18.
CONCLUSION: In the present study, despite the high prevalence of HPV types 16 and 18, the presence of these
virus types did not affect the prognosis of patients with stage I cervical cancer who underwent radical
hysterectomy.
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& INTRODUCTION
Cervical cancer is the second most common type of cancer
among women in Brazil (1,2), and in 2012, it was estimated
that 17,540 new cases of cervical cancer would occur in
Brazil (approximately 17 cases in every 100,000 women) (3).
Human papilloma virus (HPV) has been identified as a key
factor in the development of cervical cancer (4-6). Among
the HPV types classified as high-risk, HPV 16 and HPV 18
are responsible for the largest percentage of cervical cancer
cases (6,7).
Many prognostic factors for cervical cancer have been
established, including clinical staging, pelvic lymph node
involvement, parametrial involvement and lymphovascular
space invasion (8-11).
Cervical cancer screening studies have reported that the
prevalence of HPV infection in Brazil ranges from 15% to
27%, according to hybrid capture (HC) or polymerase chain
reaction (PCR) assays (12,13). In patients with cervical
cancer, HPV DNA has been detected in 55.2% to 91% of
patients, depending on the type of biological material and
the method used (14,15).
For almost 2 decades, studies have indicated the
possibility that HPV 18 may negatively affect the prognosis
of cervical cancer patients (7,11,16-18). Furthermore, a
significant association was found between lymphovascular
space invasion and lymph node involvement and the
presence of both HPV 16 and 18 (17). Nevertheless, other
studies have reported varying results; some have implicated
HPV 16 as an unfavorable factor, while others have failed to
detect any differences between these 2 virus types (17,19).
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Attempts have also been made to correlate the viral load
with prognosis, and different studies have produced
conflicting reports (20).
Using immunohistochemistry, research has shown that
activation of the epidermal growth factor receptor (EGFR) is
associated with chemoradiotherapy resistance in cases of
advanced cervical cancer. As a result, EGFR activation is
also associated with a poor prognosis (21).
Investigation of the EGFR status in early stage tumors has
revealed that the lack of expression of the phosphatase and
tensin (PTEN) tumor suppressor gene is associated with
metastases to pelvic lymph nodes (22). This same line of
research demonstrated that PTEN expression decreases
progressively from normal cervical tissue to cervical
intraepithelial neoplasia to squamous cell carcinoma. On
the other hand, the expression of survivin, a protein
encoded by an anti-apoptotic gene, was shown to increase
as the neoplasia progresses. Thus, PTEN and survivin
expression levels may serve as indices for evaluating
prognosis (23).
When an invasive tumor is confined to the cervix, i.e.,
stage IB cervical cancer, it is often treated using the classic
surgical technique known as the Wertheim-Meigs hyster-
ectomy, a radical hysterectomy with pelvic lymphadenect-
omy (11). Nevertheless, radiotherapy also produces results
of similar efficacy (24).
The objective of this study was to evaluate the prevalence
of HPV types 16 and 18 in women with stage IB cervical
cancer who underwent a radical hysterectomy with pelvic
lymphadenectomy and to establish a correlation between
HPV type and cancer prognosis.
& MATERIALS AND METHODS
Sample selection
A cohort study was conducted in the Arau´jo Jorge Hospital
in Goiaˆnia, Goia´s, Brazil. The charts of 160 women with stage
I invasive cervical cancer who underwent a radical hyster-
ectomy with lymphadenectomy between 1992 and 2003 were
reviewed. This study was designed to include only those
patients at clinical stage IB who had received a radical
hysterectomy with pelvic lymphadenectomy. All of the
patients were treated at a single institution in the city of
Goiaˆnia, Goia´s, Brazil. The clinical and pathological data
were analyzed according to HPV type to evaluate their effects
on tumor recurrence and overall survival. The study was
approved by the institution’s internal review board (approval
letter number 027/07). To analyze overall survival, an active
attempt was made to contact the patients by telephone and
telegram with the objective of reducing the rates of censoring
due to loss to follow-up.
Samples
A total of 92 biopsies of the cervix (samples fixed in
formalin and embedded in paraffin) were selected from the
hospital’s anatomopathology department and tested for
HPV using PCR. The molecular analysis was performed at
the Oncology Research Institute (IPON) of the Federal
University of Triaˆngulo Mineiro (UFTM), Uberaba, Minas
Gerais, Brazil.
DNA extraction from paraffin-embedded samples
The paraffin-embedded blocks were cut into 5-mm-thick
sections and placed in 2-ml Eppendorf tubes. They were
then submitted to the following deparaffinization process.
Briefly, 1 ml of 97% xylol was added to each microtube, and
the mixture was homogenized in a vortex mixer, heated in
an oven at 60 C˚ for 10 minutes and centrifuged at 2,500 rpm
for 10 minutes. The excess xylol was removed, and the
quality of the DNA was verified using b-actin. Next, 200 mL
of chloroform was added for each 1.0 ml of TRIZOLH. The
mixture was then vortexed for 15 seconds, incubated at
room temperature for 3 minutes and centrifuged at 12,000 g
for 15 minutes at 4 C˚. Next, the pellets were washed twice in
300 ml of 100% ethanol, and then 1 ml of 75% ethanol was
added. The material was placed in the refrigerator and
allowed to dry for 12 hours before posterior amplification of
the sample. At the time of use, this precipitate was again
suspended in Tris-acetate-EDTA buffer.
HPV genotyping and DNA amplification cycle
To identify molecular HPV and b-actin, PCR amplifica-
tion was performed. The reaction mixture contained 5.0 ml
106 buffer, 1.0 ml dNTPs (10 mM), 1.5 ml 50 mM MgCl2,
0.2 ml Taq DNA polymerase and distilled H2O to a final
volume of 50.0 ml. The reaction mixture was then added to a
tube containing 1.0 ml primer and 4.0 ml of DNA to reach a
final volume of 50.0 ml. Type-specific primers for HPV 16
(5’ = 5’ACCGAAACCGGTTAGTATAAAAGC3’ and 3’ = 5’
ATAACTGTGGTAACTTTCTGGGTC3’) with a product of
477 base pairs (bp) and primers for HPV 18 (5’ = 5’CGG
TCGGGACCGAAAACGGTG3’ and 3’ = 5’CGTGTTGGATC
CTCAAAGCGCGCC3) with a product of 422 bp were used.
b-actin primers (5’ = 5’GTGGGGCGCCCCAGGCACCA3’
and 3’ = 5’CTCCTTAATGTCACGCACGATTTC3’) with a
product of 295 bp were used as an internal control. An-
nealing was performed at 56 C˚ for each of these 3 primers
(25,26). The reaction was initiated at 94 C˚ for 1 minute for
denaturation, followed by 30 cycles of 2 minutes at 50 C˚ for
annealing and 3 minutes at 72 C˚ for polymerization. The
reaction was amplified using an Eppendorf thermal cycler.
Statistical analysis
Various clinical and pathological characteristics were
analyzed, including the age of the patient at the time of
cancer diagnosis, the number of pregnancies and deliveries
she had prior to her cancer diagnosis and the histological
type of the tumor (based on the World Health Orga-
nization’s (WHO) classifications). In addition, the following
factors were taken into consideration: the degree of
anaplasia according to the WHO classifications (grades I,
II, III or undifferentiated), whether there was lymphovas-
cular invasion and whether the pelvic lymph nodes were
affected. Because the study objective was to characterize the
sample of patients with cervical cancer, descriptive analyses
rather than statistical analyses were initially performed on
the study variables mentioned above. The differences in
parameters between the groups were assessed using the chi-
square test and Fisher’s exact test, as appropriate. To
calculate survival, the Kaplan-Meier method was used,
while the log-rank test was applied to compare the mean
survival rates associated with different possible prognostic
factors for cervical cancer. In calculating the overall
survival, all deaths were taken into consideration, regard-
less of their cause. For cancer-associated survival, the
criterion applied was the event (i.e., the recurrence of
locoregional or metastatic disease). The patients who were
alive at the time of the last medical follow-up visit or who
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died after 60 or more months of follow-up were considered
censured. P-values ,0.05 were considered statistically
significant for all tests. The Statistical Package for the
Social Sciences (SPSS), version 15.0 for Windows (SPSSH,
Chicago, IL, USA), was used for all statistical analyses.
& RESULTS
The ages of the patients in this study ranged from 26 to 64
years, with a mean of 40¡8.95 years (standard deviation
[SD]). The mean duration of follow-up was 67 months
(range 4-134 months; median 73 months; SD 44.14 months).
Of the 86 patients studied, 8 suffered a disease recurrence,
and 4 of these patients died during the study. Only 1 patient
had a diagnosis of vaginal intraepithelial neoplasia (VAIN)
III during the clinical follow-up period, and this condition
regressed spontaneously. The VAIN III diagnosis occurred 2
years after the patient had been treated for a recurrence of
the pelvic tumor. This recurrence was treated with radio-
therapy, and there is currently no sign of disease in this
patient. The demographic, clinical and pathological char-
acteristics of the patients who tested positive for HPV 16
and 18 are shown in Table 1.
With respect to genotype, HPV 16 alone was found in 30
samples, whereas HPV 18 alone was detected in only 5
samples. The concomitant presence of both types of HPV
was detected in 21 samples. In 22 samples, neither of these
viral types was detected.
With regard to the histological type, HPV 18 was detected
in 84.6% of squamous cell carcinomas (22 cases), in 7.7% of
adenocarcinomas (2 cases) and in 7.7% of adenosquamous
cell carcinomas (2 cases). HPV 18 was not detected in any
cases of undifferentiated carcinoma. HPV 16 was detected in
85.2% of squamous cell carcinomas (46 cases), in 9.3% of
adenocarcinomas (5 cases) and in 5.6% of adenosquamous
carcinomas (3 cases).
Regarding the degree of anaplasia, in tumors that tested
positive for HPV 18, the prevalence of grade II (moderately
differentiated) was 70.8% (17 cases), while 25% (6 cases) of
the tumors were classified as grade III (highly differentiated).
For the tumors that tested positive for HPV 16, the
prevalence of grade II anaplasia was 66% (33 cases), while
16 cases (32%) were classified as grade III and 1 case (2%) as
grade I.
In this sample, only 5 cases were found in which the
pelvic lymph nodes were affected by the neoplasia. HPV 18
was detected in 2 of these cases (7.7%), and HPV 16 was
detected in another 2 cases (5.6%).
Lymphovascular invasion associated with HPV 18 was
observed in 29.4% of the 63 cases for which this information
was available in the patients’ charts. With respect to HPV
16, lymphovascular invasion was found in 66.7% of the 66
cases for which this variable was provided.
The majority of recurrences occurred within 30 months
after the initial treatment was completed, and the 5-year
disease-free survival rate was 91%. The eighth recurrence is
not shown on the survival curve because it occurred after 60
months. The 5-year overall survival rate in the study group
was 95%. The 5-year disease-free survival rates were 92%
and 88% for the patients who tested positive and negative
for HPV 16, respectively (p.0.05). The 5-year disease-free
survival rates were 83% and 93% for those who tested
positive and negative for HPV 18, respectively, and there
were no statistically significant differences between the
groups.
The overall survival rate among women who tested
positive for HPV 16 was 94% compared to 96% among those
who tested negative (p.0.05) (Figure 1A). The women who
tested positive for HPV 18 had an overall 5-year survival
rate of 91% compared to 96% among those who tested
negative (p.0.05) (Figure 1B). When disease-free survival
was analyzed in relation to the other independent variables,
none of the factors evaluated were associated with cervical
cancer recurrence (Figure 1). Furthermore, none of the
factors evaluated in this study were found to affect overall
survival, as shown in Table 2.
& DISCUSSION
Of the various prognostic factors for cervical cancer, the
clinical staging system proposed by the International
Federation of Gynecology and Obstetrics (FIGO) remains
the most significant, with a 5-year survival rate of
approximately 90% up to clinical stage IB1. Other relevant
factors include pelvic lymph node metastases (12-20% at
clinical stage IB) and para-aortic lymph node metastases (4-
7% at clinical stage I). However, recovery rates may fall
Table 1 - Demographic, clinical and pathological
characteristics of the patients with stage I cervical cancer
who underwent radical hysterectomy and tested positive
for HPV types 16 and 18.
Characteristics HPV 16* HPV 18*




#30 5 9.3 3 11.5
30–50 39 72.2 19 73.1
.50 10 18.5 4 15.4
Clinical stage (FIGO)
IB1 46 85.2 22 84.6
IB2 8 14.8 4 15.4
Histological type
Squamous cell carcinoma 46 85.2 22 84.6
Adenocarcinoma 5 9.3 2 7.7
Adenosquamous cell carcinoma 3 5.6 2 7.7
Others 0 0 0 0
Grade of differentiation
Grade I 1 2 1 4.2
Grade II 33 66 17 70.8
Grade III 16 32 6 25
Metastases to lymph nodes
Yes 3 5.6 3 12
No 51 94.4 22 88
Angiolymphatic invasion
Yes 12 28.6 5 25
No 30 71.4 75 75
Initial treatment
Surgery alone 42 77.8 20 76.9
Surgery + radiotherapy 9 16.7 4 15.4
Radiotherapy + surgery 3 5.6 2 7.7
Recurrence of the disease
Yes 5 9.8 3 12
No 46 90.2 22 88
Treatment of recurrence
Radiotherapy 0 0 0 0
Chemotherapy 1 100 1 100
Radiotherapy + chemotherapy 0 0 0 0
* HPV-positive patients.
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considerably when the pelvic lymph nodes are involved,
and para-aortic metastases are present principally when the
pelvic lymph nodes are also affected. Parametrial invasion
and lymphovascular space invasion are also considered
relevant findings. As individual factors, age and tumor
grade are not as important as other prognostic factors,
according to a previous report by Zaino et al. (27).
In the present study, HPV 16 and 18 DNA was found in
62.7% and 30.2% of the women, respectively, which is not
surprising because the majority of women between 50-59
years of age have been shown to test positive for these HPV
types (28). In this study, HPV 16 and 18 DNA was found in
the majority of the older women between 30-50 years of age,
and this finding is also in agreement with the results of
other studies (29,30).
Previous work has shown that the presence of HPV 18
may be considered an independent prognostic factor for a
poor outcome in early stage cervical cancers (7,11,16), and
the results of the present study are in agreement with this
line of reasoning. In fact, the current study included early
stage cervical tumors precisely because the literature
indicates that the prognosis is otherwise good in these
cases.
The current study evaluated the effect of HPV 16 and 18
on the prognosis of women with early stage invasive
cervical cancer. The results demonstrated an overall 5-year
survival rate of 95%, which may be because only 10.4% of
the women in this study sample were staged as IB2 (i.e.,
tumors larger than 4 cm) according to the staging classifica-
tion of the FIGO. In other studies, the overall 5-year survival
rate for those with early stage tumors has also been high
(1,31). Nevertheless, although 5-year survival rates for
small-volume tumors are usually as high as 90%, the
survival rates for larger tumors may fall to 70% after 5
years (32).
The most prevalent histological type was squamous cell
carcinoma, which was present in 84.4% of the cases
evaluated in this study, followed by adenocarcinoma and
adenosquamous cell carcinoma, which were found in 12.4%
of the cases. These findings are in agreement with the data
published in the literature (7,11). However, it remains
controversial as to whether adenosquamous carcinoma is
associated with a poor prognosis; although some authors
advocate this hypothesis (33), others argue that there is no
supporting evidence (24).
Adenocarcinomas were not associated with a greater
likelihood of tumor recurrence or a poorer prognosis in this
study group, and only 1 patient experienced tumor
recurrence. HPV 18 was only associated with 1 case of
adenocarcinoma and 2 cases of adenosquamous cell
carcinoma. Furthermore, 20 cases of adenocarcinoma had
to be excluded from the study because it was impossible to
recover the corresponding paraffin blocks from the anato-
mopathology department, and it is possible that this
exclusion may have affected the final results.
In the present study, HPV type had no effect on the
disease-free or overall survival rates and appeared to have
no effect on the likelihood of tumor recurrence.
Numerous prognostic factors for cervical cancer have
been documented in the literature, including clinical
staging, invasion of the lymph nodes by tumor cells,
parametrial involvement and invasion of the lymphovas-
cular space (8,9,10,11). Nonetheless, various investigators
have attempted to clarify the precise role of HPV type in
tumor progression (7,11,34-37).
In this study, the number of cases in which the tumor had
invaded the pelvic lymph nodes was small (5 cases, 5.5%).
Of the 8 patients who experienced recurrences, pelvic
lymphatic metastasis was present in only 1 patient.
Lymphatic metastasis is considered one of the most
important prognostic factors and one that may affect
survival. In turn, lymphatic metastasis can be affected by
angiolymphatic invasion, an increase in tumor size or the
depth of the stromal invasion, as shown in a study
conducted by the Gynecology Oncology Group (10,32).
The small number of recurrences in the present study may
also be attributable to the fact that there were few cases in
which the lymph nodes were affected.
Figure 1 - (A) Disease-free survival according to whether HPV 16 was detected. (B) Disease-free survival according to whether HPV 18
was detected.
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When a specific analysis was conducted on patients with
early stage tumors (IB and IIA) who had undergone radical
hysterectomy and pelvic lymphadenectomy, it was found
that women with HPV 18 tended to have a poorer prognosis
(7). In another study, the presence of HPV 18 in patients
with early cervical carcinoma was associated with a
significantly poorer prognosis compared to women infected
with HPV 16, even after adjusting for other relevant factors,
such as clinical stage, lymph node status and histological
type (12). Nevertheless, in a study conducted in Russian
women is not observed in HPV type influences the
prognosis of women, which had staged tumors classified
as stage I and stage II (19). However, in that study, no
specific analysis was performed with respect to the type of
treatment used, unlike the study mentioned previously (19).
In the study of van Muyden et al. 1999, HPV was detected in
all cases studied, corroborating the hypothesis that HPV-
negative cervical cancer does not exist (5,19).
It has also been reported that tumors positive for HPV 16
are more likely to metastasize to the pelvic and parametrial
lymph nodes compared to HPV-16-negative tumors (38) and
that HPV 16 negatively affects the prognosis of patients who
receive a radical hysterectomy with pelvic lymphadenect-
omy (39). A study conducted by Pilch et al. (17) found a
significant association between involvement of the lymph
nodes and the lymphovascular space and the presence of
HPV types 16 and 18. However, in the present study, the
presence of HPV 16, although more prevalent, had no effect
on the characteristics mentioned above.
Multiple-type HPV infection has been associated with a
poorer response to radiotherapy and a poorer prognosis in
patients with local advanced cervical cancer (31,40).
Nevertheless, for the patients evaluated in the present
study, concomitant infection with HPV 16 and 18 had no
detrimental effect on their prognosis.
In recent years, some studies have tried to establish HPV
18 as an indicator of an unfavorable clinical progression. In
this respect, the present study sought to select a more
homogenous group of women with early cervical cancer
(i.e., restricted to clinical stage IB) to evaluate whether HPV
18 had a negative effect on their prognosis. However, it was
difficult to obtain an adequate number of cases because an
unexpected number of charts (230) could not be located by
the Department of Medical Records and Statistics of the
Arau´jo Jorge Hospital. Furthermore, due to a similar
situation in the anatomopathology department, it was
impossible to recover the paraffin blocks of tumor samples
for 68 patients who were eligible for the study, a fact that
certainly contributed to the inadequate number of cases for
the projected analysis.
Furthermore, it was impossible to identify any factor
analyzed that was significantly associated with disease
recurrence, which may have been due to the limited size
and homogeneity of the sample or the effect of other factors
that are still under investigation.
In the present study, the prevalence of HPV 16 in the study
group was greater than the prevalence of HPV 18. However,
the presence of HPV 16 or 18 was unrelated to the histological
type and the degree of anaplasia, vascular invasion or lymph
node involvement. Despite the high prevalence of HPV 18
and/or HPV 16, the presence of these HPV types did not
affect the prognosis of the study patients with stage I cervical
cancer who underwent radical hysterectomy.
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Table 2 - Univariate analysis of the presence or absence of
recurrence according to the clinical and pathological
characteristics and the HPV type in women with stage IB
cervical cancer.
Recurrence
Variable Yes No p-value* RR (95% CI)
n % n %
Age group
#39 years 5 13.5 32 86.5 1
40-64 years 3 6.5 41 93.5 0.283 2.240
(0.498-0.064)
Clinical staging
IB1 7 9.3 68 90.7 1
IB2 1 12.5 7 87.5 0.572 0.721
(0.077–6.735)
Pregnancies
1-3 pregnancies 2 9.1 20 90.9
.4 pregnancies 6 10 55 90 0.635 0.900
(0.168–4.832)
Deliveries
1-3 deliveries 1 3.1 31 96.9 1





7 9.7 65 90.3 1
Non-squamous
cell carcinoma
1 9.1 10 90.9 0.947 1.077
(0.120–9.705)
Lymph nodes
None 7 9 71 91
.1 1 25 3 75 0.342 3.381
(0.309-6.996)
Treatment
Hysterectomy 5 8.1 57 91.9 1
Other treatments 3 14.3 18 85.7 0.604 0.526
(0.114–2.422)
HPV 16
Negative 3 10.7 25 89.3 1
Positive 5 9.8 46 90.2 0.898 1.104
(0.243–5.007)
HPV 18
Negative 5 9.8 46 90.2 1
Positive 3 12 22 88 0.769 0.797
(0.175–3.640)
*Fischer’s exact test.
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